Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
 We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

For patient resources and support click HERE

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

About HYMPAVZIAbout
HYMPAVZIOverviewHYMPAVZI in ActionEfficacyEfficacyStudy DesignPrimary EndpointsSecondary EndpointsSafetyDosing & AdminDosing 

& AdminDosingPen OverviewInjection OverviewPatient StoriesPatient
StoriesMeet a Real PatientIdentifying Potential PatientsResourcesResourcesResourcesPatient Savings & Support
Full Prescribing InformationPatient InformationInstructions for UseIndication Patient Site

For routine prophylaxis in patients 12 years and older with hemophilia A or B without inhibitors1

Only HYMPAVZI is a once-weekly, fixed-dose* pen that delivers proven bleed protection† and demonstrated safety profile1,2‡The first FDA-approved rebalancing therapy for hemophilia2,3 See the clinical data of HYMPAVZI Loading For routine prophylaxis in patients ages 6 years and older with hemophilia A or B, with or without inhibitors1Only HYMPAVZI is a once-weekly, fixed-dose† pen that delivers proven bleed protection* and demonstrated safety profile1-3‡Only HYMPAVZI is a once-weekly, fixed-dose† pen that delivers proven bleed protection* and demonstrated safety profile1-3‡The first FDA-approved rebalancing therapy for hemophilia2,3
See the clinical data for HYMPAVZI
Loading Innovative mechanism of action: anti-TFPI1,4-7§

Designed to help prevent or reduce bleeding episodes1

 Watch how HYMPAVZI works LoadingSafety profile

Safety of HYMPAVZI was evaluated in the Phase 3 BASIS study1

 See safety data Loading Designed with convenience in mind

No mixing, measuring, or lengthy prep. The same dose every week (after the loading dose) regardless of weight or activity level1

 Watch the Instructions for Use LoadingIn the BASIS study, patients ages 12+ without inhibitors achieved a 92% reduction in treated bleeds on HYMPAVZI compared to on-demand factor-based treatment (3.2 annualized bleed rate [ABR] vs 39.9 ABR) and 35% reduction in treated bleeds on HYMPAVZI compared to routine factor-based prophylaxis treatment (5.1 ABR vs 7.9 ABR). Patients 12+ with inhibitors achieved a 93% reduction in treated bleeds on HYMPAVZI compared to on-demand bypass treatment (1.4 ABR vs 19.8 ABR). The BASIS KIDS study is an ongoing study. For patients ages 6 to <18 without inhibitors, the mean ABR of treated bleeds on HYMPAVZI was 1.8. For patients ages 6 to <18 with inhibitors, the mean ABR of treated bleeds on HYMPAVZI was 1.4.1For children ages 6 to <12, the recommended loading dose is 150 mg on day 1, then 75 mg weekly maintenance dose starting day 8. For adults and adolescents ages 12+, the recommended loading dose is 300 mg on day 1, then 150 mg weekly maintenance dose starting day 8. When control of bleeding events is judged to be inadequate, dose adjustment may be considered.1In the BASIS and BASIS KIDS studies, the most common adverse reactions included injection site reaction, headache, pyrexia, arthralgia, diarrhea, pruritus, and rash.1HYMPAVZI is a TFPI antagonist.1Meet Peter, a real HYMPAVZI patient

Hear Peter's experience using once-weekly HYMPAVZI1

 See Peter’s story Loading See Peter’s story Loading
Stay up to date on HYMPAVZI

Be the first to know about product updates, events, and more. 

 Sign up Loading Sign up LoadingABR=annualized bleed rate; TFPI=tissue factor pathway inhibitor.References:1. HYMPAVZI. Prescribing Information. Pfizer Inc.; 2026. 2. U.S. FDA approves Pfizer's HYMPAVZI™ (marstacimab-hncq) for the treatment of adults and adolescents with hemophilia A or B without inhibitors; 2024. Accessed December 23, 2025. https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-hympavzitm-marstacimab-hncq 3. FDA approves novel treatment for hemophilia A or B, with or without factor inhibitors; 2025. Accessed December 23, 2025. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-hemophilia-or-b-or-without-factor-inhibitors 4. Butterfield JSS, et al. Mol Ther. 2020;28(3):997-1015. 5. Srivastava A, et al. Haemophilia. 2020;26(suppl 6):1-158. 6. Pittman DD, et al. Res Pract Thromb Haemost. 2022;6(2):e12679. 7. Ozelo MC, et al. Res Pract Thromb Haemost. 2022;6(3):e12695. 8. Center for Biologics Evaluation and Research, US Food and Drug Administration, US Department of Health and Human Services. CBER Approval Letter, Coagulation Factor IX (Recombinant), Genetics Institute, Inc. February 11, 1997. Accessed February 27, 2025. https://wayback.archive-it.org/7993/20170723024338/https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm057039.htmHYMPAVZI is a registered trademark of Pfizer Inc.

To report an adverse event, please call 1‑800‑438‑1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2026 Pfizer Inc. All rights reserved.

PP-HYM-USA-1138
Indications and usageHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with:
  • hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors, or
  • hemophilia B (congenital factor IX deficiency) with or without factor IX inhibitors.
Helix ISI Modal Headline Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Important Safety InformationHYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist, and may increase the risk of thromboembolic complications. Venous and arterial thromboembolic events were reported in 0.8% of patients (2/259) in the open-label extension study. Patients with independent risk factors for thromboembolic events may be at increased risk of thromboembolic events with use of HYMPAVZI. Consider the benefit and risk of using HYMPAVZI in patients with known risk factors for thromboembolism. Interrupt HYMPAVZI prophylaxis if diagnostic findings consistent with thromboembolism occur and manage as clinically indicated. If factor VIII or factor IX products or bypassing agents are indicated in a patient receiving HYMPAVZI prophylaxis, the minimum effective dose according to the product label is recommended. Inform patients of signs and symptoms of thromboembolic events. Monitor patients for thromboembolic events.

HYMPAVZI may cause hypersensitivity reactions (including, but not limited to, urticaria and pruritus). If HYMPAVZI-treated patients develop a severe hypersensitivity reaction, advise patients to discontinue HYMPAVZI and seek immediate emergency treatment.

Based on its mechanism of action, HYMPAVZI may cause fetal harm when administered to a pregnant woman. Verify that females of reproductive potential are not pregnant prior to initiating HYMPAVZI. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with HYMPAVZI and for 2 months after the last dose.

HYMPAVZI can cause increased levels of fibrin D-dimer and prothrombin fragment 1.2. For patients taking HYMPAVZI, these coagulation biomarkers may not be reliable predictive markers for clinical decision-making with suspicion of thrombosis such as deep vein thrombosis (DVT) and pulmonary embolism (PE).

Adverse reactions reported in ≥2% of patients treated with HYMPAVZI in clinical trials in adult and pediatric patients 6 years and older with hemophilia A or B with or without inhibitors included injection site reaction (12%); headache, including headache and migraine (7%); pyrexia (6%); arthralgia (3%); diarrhea (3%); pruritus (2%); rash (2%).

Consider contacting the Poison Help Line (1-800-222-1222) or a medical toxicologist for overdose management recommendations.IndicationsHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with:
  • hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors, or
  • hemophilia B (congenital factor IX deficiency) with or without factor IX inhibitors.